Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
Reid Rubsamen(University Hospitals of Cleveland), Paul E. Harris(Flow Pharma (United States)), Richard T. Carback(Flow Pharma (United States)), Christopher Massey(The University of Texas Medical Branch at Galveston), Trevor Brasel(The University of Texas Medical Branch at Galveston), Scott Burkholz(Flow Pharma (United States)), Lu Wang(Children's Hospital of Philadelphia), Tom Hodge(Flow Pharma (United States)), C.v. Herst(Flow Pharma (United States))
Cited by 9
Related Papers
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
|Clinical Infectious Diseases|2020|501
BATF–JUN is critical for IRF4-mediated transcription in T cells
|Nature|2012|473
Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages
|Nature Immunology|2011|471
Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study
|American Journal of Clinical Nutrition|2003|360